


Ask a doctor about a prescription for SUMATRIPTAN TEVA 50 mg FILM-COATED TABLETS
Patient Information Leaflet
Sumatriptan Teva 50 mg film-coated tablets EFG
Read the entire leaflet carefully before starting to take the medicine, as it contains important information for you.
people, even if they have the same symptoms as you, as it may harm them.
Contents of the leaflet:
receptor)
Do not take Sumatriptan Teva
Warnings and precautions
Before prescribing Sumatriptan, your doctor will determine if your headache is caused by migraine and not by any other disease.
Consult your doctor or pharmacist before starting to take Sumatriptan Teva:
for epileptic seizures;
of sulfonamides;
Other medicines and Sumatriptan Teva
Certain medicines may affect the efficacy of Sumatriptan, and Sumatriptan may affect the efficacy of other medicines. Contact your doctor if you use:
Inform your doctor or pharmacist if you are taking or have recently taken or would need to take other medicines.
Pregnancy and breastfeeding
Pregnancy:
Consult your doctor or pharmacist before using any medicine.
Only limited information is available on the safety of Sumatriptan in human pregnancy. So far, these data do not indicate a higher risk of malformations. It is recommended that you do not take Sumatriptan Teva during pregnancy, unless your doctor advises you to do so.
Breastfeeding:
Consult your doctor or pharmacist for advice on using this medicine during breastfeeding.
Sumatriptan is excreted in breast milk. You can minimize your baby's exposure by avoiding breastfeeding for 12 hours after administration of Sumatriptan Teva, during which time the expressed milk should be discarded.
Driving and using machines
Migraine itself or its treatment with Sumatriptan Teva may cause drowsiness. Do not drive or operate machines if you are affected.
Sumatriptan Teva contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult them before taking this medicine.
Sumatriptan Teva contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per film-coated tablet; this is essentially "sodium-free".
Follow the administration instructions of this medicine exactly as indicated by your doctor or pharmacist. Consult your doctor or pharmacist if you have doubts.
Sumatriptan Teva should not be taken to prevent migraine attacks, as it is intended to treat migraine attacks. Sumatriptan Teva should be taken as soon as migraine pain appears; however, it is equally effective when taken in an advanced state of the attack.
The recommended dose for adults is 50 mg. For some patients, 100 mg may be necessary. If Sumatriptan Teva does not provide immediate relief, it is not beneficial to take more tablets for this attack. Sumatriptan Teva can be used for your next attack. If, after your first dose, your migraine disappears but then returns, you can take another tablet, provided that at least 2 hours have passed since you took the first tablet.
Do not take more than 300 mg (six50 mg tablets or three100 mg tablets) in 24 hours.
Use in children and adolescents
The use of Sumatriptan Teva 50 mg is not recommended in children, adolescents, and patients over 65 years old. For patients with mild to moderate liver problems, low doses of 25-50 mg should be used.
Method of administration
Swallow the tablet whole with water.
If you take more Sumatriptan Teva than you should
The symptoms of overdose are the same as those listed in section 4 "Possible side effects". If you have taken too many tablets, consult your doctor, pharmacist, or call the Toxicology Information Service (tel.: 91 562 04 20), indicating the product and the amount ingested.
If you have any other doubts about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can have side effects, although not everyone gets them. Consult your doctorif you need to clarify this.
The following side effects are possible with the following frequencies:
Frequent: may affect up to 1 in 10 people
Very rare: may affect up to 1 in 10,000 people
If you need to have a blood test to check your liver function, Sumatriptan Teva may affect your results.
Unknown: frequency cannot be estimated from available data:
If a severe allergic reaction occurs, stop taking Sumatriptan Teva and contact your doctor immediately.
Reporting side effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are side effects not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use Sumatriptan Teva after the expiration date that appears on the carton/blister. The expiration date is the last day of the month indicated after CAD.
This medicine does not require special storage conditions.
Medicines should not be disposed of through wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Sumatriptan Teva
The active ingredient is sumatriptan. Each tablet contains 50 mg of sumatriptan (as succinate).
The other ingredients are:
Appearance of Sumatriptan Teva and package contents
Sumatriptan Teva are film-coated tablets of peach to pink color, oblong shape, engraved with "5" and "0" on one side and with a score line on each side.
The tablet can be divided into equal doses.
The product is available in pack sizes of 2, 3, 4, 6, 12, 18, 24, 30, and 50 tablets.
It may be that only some pack sizes are marketed.
Marketing Authorization Holder
Teva Pharma, S.L.U.
C/ Anabel Segura, 11, Edifício Albatros B, 1ª planta,
Alcobendas, 28108 - Madrid
Manufacturer
Teva Pharmaceutical Works Private Limited Company
H-4042 Debrecen, Pallagi str. 13
Hungary
or
Pharmachemie B.V.
Swensweg 5
Postbus 552
2003 RN Haarlem – Netherlands
This medicine is registered in the EEA Member States with the following names
Bélgica: Sumatriptan TEVA 50 mg filmomhulde tabletten
Dinamarca: Sumatriptan Teva
España: Sumatriptán TEVA 50 mg comprimidos recubiertos con película EFG
Finlandia: Sumatriptan Teva 50 mg tabletti kalvopäällysteinen
Francia: Sumatriptan TEVA 50 mg comprimé pelliculé
Hungría: Sumatriptan-Teva 50 mg tabletta
Italia: Sumatriptan Teva 50 & 100 mg compresse rivestite con filme
Luxemburgo: Sumatriptan TEVA 50 mg comprimés pelliculés
Países Bajos: Sumatriptan 50 mg PCH, filmomhulde tabletten
Noruega: Sumatriptan Teva 50 mg tabletter, filmdrasjerte
Suecia: Sumatriptan Teva 50 mg filmdragerade tabletter
Reino Unido: Sumatriptan 50 mg Film-coated Tablets
Date of the last revision of this leaflet:April 2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS)
http://www.aemps.gob.es
You can access detailed and updated information about this medicine by scanning the QR code included in the packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/68727/P_68727.html
The average price of SUMATRIPTAN TEVA 50 mg FILM-COATED TABLETS in November, 2025 is around 12.18 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for SUMATRIPTAN TEVA 50 mg FILM-COATED TABLETS – subject to medical assessment and local rules.